Venus-P self-expandable valves were associated with a higher rate of new-onset ventricular arrhythmias compared to ES3 balloon-expandable valves (21.1% vs 3.2%; P<0.001) postoperatively.
Cohort (n=145)
Do self-expandable valves compared to balloon-expandable valves affect early safety and hemodynamic outcomes in patients undergoing transcatheter pulmonary valve replacement for dysfunctional right ventricular outflow tracts?
Self-expandable valves for transcatheter pulmonary valve replacement are effective but associated with a higher rate of transient early postoperative ventricular arrhythmias compared to balloon-expandable valves.
Absolute Event Rate: 21.1% vs 3.2%
p-value: p=<0.001
BACKGROUND: Self-expandable valves are emerging complements to balloon-expandable valves for transcatheter pulmonary valve replacement in dysfunctional right ventricular outflow tracts, though their safety and efficacy remain underexplored. We aim to compare patient characteristics and outcomes of self-expandable valves and balloon-expandable valves in transcatheter pulmonary valve replacement. METHODS: Baseline and early follow-up data were prospectively analyzed for 145 patients who underwent transcatheter pulmonary valve replacement with Edwards SAPIEN 3 (ES3) balloon-expandable valves or Venus-P self-expandable valves (January 2022–December 2024). An independent adjudication expert analyzed and classified adverse events. RESULTS: Cohort: 58.6% males, median weight of 65 kg, median age of 36.3 years; 64.1% of ES3, 35.9% of Venus-P. Tetralogy of Fallot was present in 55.2%, with native/patched right ventricular outflow tracts in 41.9% of ES3 and 100% of Venus-P cases ( P <0.001). Severe pulmonary regurgitation was found in 64.5% of ES3 and 100% of Venus-P ( P <0.001). Median valve diameter was 26 mm (Q1–Q3: 23–29) for ES3 and 36 mm (32–36) for Venus-P ( P <0.001). All implantations were successful, with no significant difference in procedure or fluoroscopy times between groups. Postoperative median right ventricular outflow tract maximum velocity was 2.2 m/s (1.9–2.6) for ES3 and 1.6 m/s (1.1–1.8) for Venus-P ( P <0.001). Procedural and vascular-access adverse events occurred in 14 patients (ES3: 9.7%, Venus-P: 9.6%; P =0.992), including 8 moderate and 1 major (ES3: 5.4%, Venus-P: 7.7%; P =0.582). New-onset ventricular arrhythmias occurred in 14 patients (ES3: 3.2%, Venus-P: 21.1%; P <0.001), including 5 classified as moderate adverse events, all in Venus-P ( P =0.002). All arrhythmias resolved with short-term therapy; no permanent antiarrhythmics or ablations were needed. CONCLUSIONS: Self-expandable valves are effective for transcatheter pulmonary valve replacement but linked to higher transient arrhythmic adverse event rates than balloon-expandable valves in the early postoperative period.
Haddad et al. (Fri,) conducted a cohort in Dysfunctional right ventricular outflow tracts (n=145). Venus-P self-expandable valves vs. Edwards SAPIEN 3 (ES3) balloon-expandable valves was evaluated on New-onset ventricular arrhythmias (p=<0.001). Venus-P self-expandable valves were associated with a higher rate of new-onset ventricular arrhythmias compared to ES3 balloon-expandable valves (21.1% vs 3.2%; P<0.001) postoperatively.